Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 4/20 | 0.35 |
| ▸ | NPY4R | P50391 | 4/20 | 0.35 |
| ▸ | NPY1R | P25929 | 3/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.33 |
| ▸ | NPY2R | P49146 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.31 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KLK7 | P49862 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19681474 | 0.93 | NPY5R (0.39) | NPY5RNPY4RNPY1RAKT1C3AR1 | |
| SCHEMBL20935183 | 0.92 | NPY4R (0.36) | NPY5RNPY4RNPY1RAKT1C3AR1 | |
| SCHEMBL20935173 | 0.90 | ELANE (0.34) | NPY5RNPY4RNPY1RAKT1C3AR1 | |
| SCHEMBL17722924 | 0.89 | NPY5R (0.39) | NPY5RNPY4RNPY1RAKT1C3AR1 | |
| SCHEMBL20935175 | 0.89 | KISS1R (0.35) | NPY5RNPY4RNPY1RAKT1C3AR1 | |
| SCHEMBL18909037 | 0.88 | NPY5R (0.36) | NPY5RNPY4RNPY1RAKT1C3AR1 | |
| SCHEMBL21861765 | 0.88 | NPY5R (0.36) | NPY5RNPY4RNPY1RAKT1C3AR1 | |
| SCHEMBL20889020 | 0.87 | NPY5R (0.36) | NPY5RNPY4RNPY1RAKT1C3AR1 | |
| SCHEMBL21034051 | 0.86 | NPY5R (0.35) | NPY5RNPY4RNPY1RAKT1C3AR1 | |
| SCHEMBL23436487 | 0.86 | NPY5R (0.33) | NPY5RNPY4RNPY1RC3AR1NPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-12037378-B2 | Variant CD58 domains and uses thereof | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| US-20230128499-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISEASES | NOVARTIS AG (CH) | 2023-04-27 | — | — | US | disclosed |
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230037682-A1 | BINDING MOLECULES AGAINST CD3 AND USES THEREOF | NOVARTIS AG (CH) | 2023-02-09 | — | — | US | disclosed |
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | NOVARTIS AG (CH) | 2022-12-15 | — | — | US | disclosed |
| US-20220089772-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2022-03-24 | — | — | US | disclosed |
| US-11161911-B2 | Anti-glyco-MUC1 antibodies and their uses | GO THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20210139585-A1 | CD19 BINDING MOLECULES AND USES THEREOF | NOVARTIS AG (CH) | 2021-05-13 | — | — | US | disclosed |
| US-20200362054-A1 | TRISPECIFIC BINDING MOLECULES AGAINST TUMOR-ASSOCIATED ANTIGENTS AND USE THEREOF | NOVARTIS AG (CH) | 2020-11-19 | — | — | US | disclosed |
| US-20190119400-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | GO THERAPEUTICS, INC. (US) | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230126689-A1 | ANTI-GLYCO-CD44 ANTIBODIES AND THEIR USES | CD44, SIGLEC7, SIGLEC9 | NPY5R 4580/4885NPY4R 4437/4885NPY1R 4754/4885 |
| US-12037378-B2 | Variant CD58 domains and uses thereof | CD2, CD58, CD2BP2 | NPY5R 4419/4885NPY4R 4389/4885NPY1R 4528/4885 |
| US-20230128499-A1 | BISPECIFIC COMBINATION THERAPY FOR TREATING PROLIFERATIVE DISEASES AND AUTOIMMUNE DISEASES | CD2, CD22, CD2BP2 | NPY5R 3301/4885NPY4R 3229/4885NPY1R 2254/4885 |
| US-20210139585-A1 | CD19 BINDING MOLECULES AND USES THEREOF | CD22, BCL9, CD2 | NPY5R 2142/4885NPY4R 2508/4885NPY1R 1714/4885 |
| US-20200362054-A1 | TRISPECIFIC BINDING MOLECULES AGAINST TUMOR-ASSOCIATED ANTIGENTS AND USE THEREOF | CD2, CD2BP2, CD22 | NPY5R 4544/4885NPY4R 4500/4885NPY1R 4516/4885 |
| US-20220396631-A1 | TRISPECIFIC BINDING MOLECULES AGAINST BCMA AND USES THEREOF | CD2, CD2BP2, CD22 | NPY5R 3958/4885NPY4R 3822/4885NPY1R 3293/4885 |
| US-20220089772-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | MUC1, SIGLEC7, SIGLEC9 | NPY5R 4578/4885NPY4R 4459/4885NPY1R 4680/4885 |
| US-20230037682-A1 | BINDING MOLECULES AGAINST CD3 AND USES THEREOF | CD2, CD4, CD14 | NPY5R 4140/4885NPY4R 4502/4885NPY1R 3969/4885 |
| US-11161911-B2 | Anti-glyco-MUC1 antibodies and their uses | MUC1, SIGLEC7, SIGLEC9 | NPY5R 4578/4885NPY4R 4459/4885NPY1R 4680/4885 |
| US-20190119400-A1 | ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES | MUC1, SIGLEC7, SIGLEC9 | NPY5R 4578/4885NPY4R 4459/4885NPY1R 4680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.